دورية أكاديمية
أعرض في EDS

Parkinson's disease, epilepsy, and amyotrophic lateral sclerosis-emerging role of AMPA and kainate subtypes of ionotropic glutamate receptors.

التفاصيل البيبلوغرافية
العنوان: Parkinson's disease, epilepsy, and amyotrophic lateral sclerosis-emerging role of AMPA and kainate subtypes of ionotropic glutamate receptors.
المؤلفون: Vukolova MN; Department of Pathophysiology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Yen LY; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, United States.; Cellular and Molecular Physiology and Biophysics Graduate Program, Columbia University, New York, NY, United States., Khmyz MI; N. V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Sobolevsky AI; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, United States., Yelshanskaya MV; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, United States.
المصدر: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2023 Oct 24; Vol. 11, pp. 1252953. Date of Electronic Publication: 2023 Oct 24 (Print Publication: 2023).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media S.A., [2013]-
مستخلص: Ionotropic glutamate receptors (iGluRs) mediate the majority of excitatory neurotransmission and are implicated in various neurological disorders. In this review, we discuss the role of the two fastest iGluRs subtypes, namely, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors, in the pathogenesis and treatment of Parkinson's disease, epilepsy, and amyotrophic lateral sclerosis. Although both AMPA and kainate receptors represent promising therapeutic targets for the treatment of these diseases, many of their antagonists show adverse side effects. Further studies of factors affecting the selective subunit expression and trafficking of AMPA and kainate receptors, and a reasonable approach to their regulation by the recently identified novel compounds remain promising directions for pharmacological research.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Vukolova, Yen, Khmyz, Sobolevsky and Yelshanskaya.)
References: J Neurol. 2021 Oct;268(10):3744-3757. (PMID: 33754209)
Neuron. 1993 Jan;10(1):51-9. (PMID: 7678966)
Nat Neurosci. 2002 Aug;5(8):796-804. (PMID: 12080343)
Biochim Biophys Acta Mol Basis Dis. 2017 Jul;1863(7):1739-1748. (PMID: 28528135)
Cells. 2022 Jan 25;11(3):. (PMID: 35159225)
Epilepsia. 2023 Apr;64(4):1046-1060. (PMID: 36775798)
Lancet Neurol. 2018 May;17(5):416-422. (PMID: 29525492)
J Neurosci Res. 2004 Oct 15;78(2):200-7. (PMID: 15378511)
Nat Commun. 2019 Jul 12;10(1):3094. (PMID: 31300657)
Amyotroph Lateral Scler. 2010 May 3;11(3):266-71. (PMID: 19961264)
Sci Rep. 2016 Jun 28;6:28649. (PMID: 27350567)
Nature. 1984 Feb 2-8;307(5950):462-5. (PMID: 6320006)
Neuropharmacology. 2019 Oct;157:107687. (PMID: 31251995)
Eur J Neurosci. 2002 Dec;16(11):2236-40. (PMID: 12473092)
Trends Neurosci. 2007 Mar;30(3):126-34. (PMID: 17275103)
J Physiol. 2000 Aug 1;526 Pt 3:493-506. (PMID: 10922002)
Neurobiol Aging. 1994 Mar-Apr;15(2):259-60. (PMID: 7838306)
Nat Rev Neurosci. 2013 Jun;14(6):383-400. (PMID: 23686171)
CNS Drug Rev. 2002 Fall;8(3):235-54. (PMID: 12353057)
Neuron. 2014 Mar 5;81(5):1001-1008. (PMID: 24508385)
J Neurosci. 2018 Apr 18;38(16):3901-3910. (PMID: 29540547)
J Pharmacol Exp Ther. 2003 Aug;306(2):752-62. (PMID: 12730350)
Neuron. 2014 Apr 16;82(2):279-93. (PMID: 24742457)
Brain. 2016 Feb;139(Pt 2):431-43. (PMID: 26608744)
J Neurosci. 2022 Jun 1;:. (PMID: 35654603)
Curr Neuropharmacol. 2015;13(2):239-47. (PMID: 26411767)
Cell Rep. 2023 Feb 28;42(2):112124. (PMID: 36857176)
Neurosci Bull. 2016 Apr;32(2):177-82. (PMID: 26924808)
J Neurosci. 2016 Sep 21;36(38):9873-87. (PMID: 27656025)
Neuropharmacology. 2023 Nov 15;239:109671. (PMID: 37567438)
Ann Neurol. 1991 Nov;30(5):717-23. (PMID: 1662477)
J Neurochem. 2010 Jul;114(2):499-511. (PMID: 20456008)
Lancet. 1993 Jan 30;341(8840):265-8. (PMID: 8093916)
Drug Discov Today. 2015 Jan;20(1):122-8. (PMID: 25450771)
J Neurol. 2022 Feb;269(2):885-896. (PMID: 34191081)
Epilepsy Res. 2007 Apr;74(1):45-54. (PMID: 17289347)
Nat Commun. 2014 Oct 15;5:5182. (PMID: 25316086)
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:637-659. (PMID: 31580774)
Mar Drugs. 2014 Mar 06;12(3):1185-207. (PMID: 24663110)
Synapse. 2010 Feb;64(2):177-80. (PMID: 19852073)
Br J Clin Pharmacol. 2013 Feb;75(2):323-33. (PMID: 22625422)
Curr Opin Pharmacol. 2006 Feb;6(1):82-8. (PMID: 16361116)
Mov Disord. 2021 Jul;36(7):1554-1564. (PMID: 33813737)
Neurochem Res. 1999 Oct;24(10):1233-40. (PMID: 10492518)
Epilepsia. 2013 Aug;54(8):1481-9. (PMID: 23663001)
Int J Mol Sci. 2019 Sep 06;20(18):. (PMID: 31500132)
Curr Med Chem. 2014;21(31):3535-50. (PMID: 24934359)
J Neurochem. 1992 Aug;59(2):733-9. (PMID: 1629743)
Nat Med. 2016 Dec;22(12):1496-1501. (PMID: 27820603)
Epilepsia. 2003 Jan;44(1):46-53. (PMID: 12581229)
Glia. 2018 May;66(5):1016-1033. (PMID: 29380416)
Nat Biotechnol. 2011 Aug 10;29(9):824-8. (PMID: 21832997)
Adv Neurobiol. 2017;16:117-136. (PMID: 28828608)
J Parkinsons Dis. 2020;10(s1):S29-S36. (PMID: 32651336)
Seizure. 2021 Oct;91:213-227. (PMID: 34233236)
Curr Opin Pharmacol. 2015 Feb;20:46-53. (PMID: 25462292)
Muscle Nerve. 2021 Aug;64(2):215-219. (PMID: 34008857)
Neurobiol Dis. 2003 Dec;14(3):404-16. (PMID: 14678757)
Mol Pharmacol. 2011 Jun;79(6):964-73. (PMID: 21350020)
Neuropharmacology. 2015 Aug;95:234-42. (PMID: 25839899)
Neurology. 1992 Jun;42(6):1142-6. (PMID: 1603339)
Front Cell Neurosci. 2019 Mar 01;13:80. (PMID: 30881292)
Front Neurol. 2022 Mar 07;13:839985. (PMID: 35321512)
Nature. 1993 Mar 4;362(6415):59-62. (PMID: 8446170)
Ann Neurol. 1990 Jul;28(1):18-25. (PMID: 2375630)
Front Pharmacol. 2022 Oct 25;13:989717. (PMID: 36386183)
Curr Med Chem. 2018;25(19):2198-2214. (PMID: 29189118)
Int J Mol Sci. 2019 Jun 10;20(11):. (PMID: 31185581)
Epilepsia. 2011 Jul;52(7):1331-40. (PMID: 21635236)
J Neurosci. 1988 Jan;8(1):185-96. (PMID: 2892896)
Neurotoxicology. 2018 Dec;69:23-28. (PMID: 30176255)
Front Neurol Neurosci. 2014;34:95-108. (PMID: 24777134)
Life Sci Alliance. 2022 Jan 12;5(4):. (PMID: 35022247)
Epilepsy Res. 2010 Dec;92(2-3):89-124. (PMID: 20970964)
Stroke. 1993 Dec;24(12 Suppl):I148-52. (PMID: 7504338)
Lancet. 2015 Mar 7;385(9971):884-98. (PMID: 25260236)
CNS Drug Rev. 2005 Spring;11(1):77-96. (PMID: 15867954)
Arch Dis Child. 1986 Dec;61(12):1168-72. (PMID: 3101615)
Amyotroph Lateral Scler. 2011 Sep;12(5):340-4. (PMID: 21623665)
Neurochem Int. 2013 Dec;63(7):660-9. (PMID: 23266599)
Pharmacol Rep. 2016 Feb;68(1):190-5. (PMID: 26721372)
Epilepsy Res. 2003 Sep;56(1):17-26. (PMID: 14529950)
CNS Drugs. 2012 Dec;26(12):1017-32. (PMID: 23114872)
Neurosci Lett. 2003 Jun 5;343(2):81-4. (PMID: 12759169)
JAMA Neurol. 2018 Jan 1;75(1):9-10. (PMID: 29131880)
Cold Spring Harb Perspect Med. 2017 Aug 1;7(8):. (PMID: 28003278)
Neurosci Res. 2019 Jul;144:4-13. (PMID: 29944911)
Nature. 1984 May 17-23;309(5965):261-3. (PMID: 6325946)
Br J Pharmacol. 2011 Aug;163(7):1495-506. (PMID: 21323909)
Epilepsia. 2015 Jun;56(6):924-32. (PMID: 25963722)
Hum Mol Genet. 2011 Jan 15;20(2):286-93. (PMID: 20962037)
Epilepsia. 2019 Feb;60(2):303-314. (PMID: 30588604)
Front Mol Neurosci. 2018 Jan 09;10:446. (PMID: 29375307)
Neurology. 2007 Jan 30;68(5):384-6. (PMID: 17082464)
Exp Neurol. 2013 Sep;247:476-84. (PMID: 23360800)
Epilepsy Behav. 2021 Aug;121(Pt B):106832. (PMID: 31839498)
Front Neurosci. 2020 Nov 26;14:585584. (PMID: 33324150)
Pharmacol Rev. 2010 Sep;62(3):405-96. (PMID: 20716669)
J Neural Transm Park Dis Dement Sect. 1994;8(1-2):39-71. (PMID: 7534462)
Lancet Neurol. 2020 Feb;19(2):170-178. (PMID: 31521533)
Nat Rev Neurol. 2010 Apr;6(4):211-20. (PMID: 20234357)
Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107. (PMID: 15837565)
Brain Res. 2004 May 22;1008(2):236-44. (PMID: 15145761)
P T. 2016 Nov;41(11):683-698. (PMID: 27904300)
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76. (PMID: 18344392)
Cell Death Dis. 2020 Nov 10;11(11):963. (PMID: 33173027)
Neurodegeneration. 1995 Jun;4(2):209-16. (PMID: 7583686)
Br J Pharmacol. 2022 Jul;179(14):3628-3644. (PMID: 32959886)
Nat Neurosci. 2010 Feb;13(2):197-204. (PMID: 20081851)
Acc Chem Res. 2008 Jan;41(1):87-97. (PMID: 18193822)
Front Immunol. 2018 Aug 03;9:1782. (PMID: 30123217)
J Parkinsons Dis. 2022;12(1):45-68. (PMID: 34719434)
Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94. (PMID: 15180479)
Neurol India. 2019 Jul-Aug;67(4):968-978. (PMID: 31512617)
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8268-73. (PMID: 9653176)
Epilepsy Res. 2004 Sep-Oct;61(1-3):1-48. (PMID: 15570674)
Bull Exp Biol Med. 2003 Oct;136(4):352-4. (PMID: 14714080)
Eur J Neurosci. 1999 Jan;11(1):250-62. (PMID: 9987029)
Rev Neurosci. 2013;24(5):499-505. (PMID: 24077616)
Pharmacol Res. 2020 Nov;161:105128. (PMID: 32805354)
Int J Mol Sci. 2023 Jul 01;24(13):. (PMID: 37446169)
Neurosignals. 2008;16(1):41-51. (PMID: 18097159)
Curr Drug Targets. 2007 May;8(5):603-20. (PMID: 17504104)
J Chem Neuroanat. 2011 Dec;42(4):242-8. (PMID: 21167933)
Neurology. 2011 Jul 12;77(2):179-89. (PMID: 21747075)
J Med Chem. 2012 Dec 13;55(23):10584-600. (PMID: 23181587)
Epilepsy Res. 2013 Sep;106(1-2):292-5. (PMID: 23623849)
Cochrane Database Syst Rev. 2020 Jun 24;6:CD001903. (PMID: 32588435)
Transl Neurodegener. 2020 Nov 26;9(1):42. (PMID: 33239064)
Pharmacol Res. 2017 Jul;121:59-69. (PMID: 28442348)
Mov Disord. 2012 Feb;27(2):284-8. (PMID: 22161845)
Epilepsia. 2018 Nov;59(11):e172-e178. (PMID: 30324610)
Muscle Nerve. 2021 Oct;64(4):504-508. (PMID: 34322897)
Neuropharmacology. 2010 Feb;58(2):551-8. (PMID: 19654014)
Exp Neurol. 2012 Dec;238(2):93-102. (PMID: 22921461)
Neurology. 2000 Apr 25;54(8):1589-95. (PMID: 10762498)
Brain. 2013 Jul;136(Pt 7):2077-97. (PMID: 23771339)
Lancet Neurol. 2021 May;20(5):385-397. (PMID: 33894193)
J Med Chem. 2016 May 26;59(10):4753-68. (PMID: 27067148)
Oxid Med Cell Longev. 2020 Feb 13;2020:4293071. (PMID: 32215173)
Epilepsy Res. 2002 Sep;51(1-2):31-71. (PMID: 12350382)
Cephalalgia. 2014 Feb;34(2):103-13. (PMID: 23963355)
Clin Neuropharmacol. 2012 Jan-Feb;35(1):15-20. (PMID: 22222634)
Neuropharmacology. 2001;40(1):28-35. (PMID: 11077068)
J Neuroinflammation. 2011 Jan 18;8(1):5. (PMID: 21244691)
Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Sep;6(3):131-44. (PMID: 16183555)
J Neurol. 2011 Aug;258(8):1568-70. (PMID: 21384161)
J Neuropathol Exp Neurol. 2013 Oct;72(10):919-32. (PMID: 24042195)
J Parkinsons Dis. 2018;8(s1):S3-S8. (PMID: 30584159)
J Neurol Sci. 2000 Nov 1;180(1-2):29-34. (PMID: 11090861)
PLoS One. 2014 Sep 17;9(9):e108021. (PMID: 25229608)
Exp Neurol. 2020 Jan;323:113062. (PMID: 31513786)
J Neural Transm Park Dis Dement Sect. 1995;9(2-3):145-9. (PMID: 8526999)
J Pharmacol Exp Ther. 2016 May;357(2):394-414. (PMID: 26989142)
Neurology. 1991 Feb;41(2 ( Pt 1)):168-73. (PMID: 1992358)
Front Neural Circuits. 2021 Aug 17;15:711564. (PMID: 34483848)
Naunyn Schmiedebergs Arch Pharmacol. 1999 Sep;360(3):242-8. (PMID: 10543424)
Epilepsia. 2013 Nov;54(11):1922-32. (PMID: 24117347)
Nature. 2016 Nov 10;539(7628):197-206. (PMID: 27830784)
Cold Spring Harb Perspect Med. 2015 Jun 22;5(8):a022863. (PMID: 26101204)
Rev Neurol (Paris). 2016 Jan;172(1):14-26. (PMID: 26718594)
J Gen Physiol. 2019 Dec 2;151(12):1347-1356. (PMID: 31615831)
Neuropsychiatr Dis Treat. 2014 Sep 09;10:1693-705. (PMID: 25228809)
ChemMedChem. 2017 Feb 3;12(3):197-201. (PMID: 27863026)
J Neurosci. 2011 Mar 2;31(9):3243-8. (PMID: 21368036)
Cereb Cortex. 2013 Feb;23(2):323-31. (PMID: 22345355)
Exp Neurol. 2019 Dec;322:113058. (PMID: 31499061)
J Pharmacol Exp Ther. 2001 Oct;299(1):314-22. (PMID: 11561094)
Acta Neurol Scand Suppl. 2013;(197):9-18. (PMID: 23480151)
Epilepsia. 2017 Jul;58(7):1217-1226. (PMID: 28500678)
Muscle Nerve. 1982 Jan;5(1):48-53. (PMID: 7057805)
Epilepsy Res. 2007 Jan;73(1):1-52. (PMID: 17158031)
J Pharmacol Exp Ther. 2015 Jan;352(1):43-52. (PMID: 25326131)
Mov Disord. 2010 May 15;25(7):896-905. (PMID: 20461807)
Lit Med. 2014 Spring;32(1):74-104. (PMID: 25055707)
Mol Cell Neurosci. 2007 Apr;34(4):539-50. (PMID: 17254796)
Nature. 2017 Apr 20;544(7650):367-371. (PMID: 28405022)
Cell Rep. 2017 Aug 29;20(9):2156-2168. (PMID: 28854365)
Neuron. 2016 Sep 21;91(6):1305-1315. (PMID: 27618672)
Pharmacol Res Perspect. 2014 Oct;2(5):e00063. (PMID: 25505607)
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6. Vyp. 2):50-54. (PMID: 30346434)
Int J Mol Sci. 2022 Mar 19;23(6):. (PMID: 35328765)
Ann N Y Acad Sci. 2000;899:274-82. (PMID: 10863546)
Expert Opin Investig Drugs. 2014 Jan;23(1):107-13. (PMID: 24147649)
Neuropharmacology. 2018 Dec;143:38-48. (PMID: 30222983)
Synapse. 2001 Oct;42(1):40-7. (PMID: 11668589)
Epilepsia. 2019 Mar;60 Suppl 1:22-36. (PMID: 29953584)
J Physiol. 2021 May;599(10):2655-2671. (PMID: 33533533)
Ann Neurol. 1996 May;39(5):574-8. (PMID: 8619541)
NPJ Parkinsons Dis. 2018 Sep 27;4:30. (PMID: 30302391)
Epilepsia. 1995 Jun;36(6):566-71. (PMID: 7555968)
Nat Neurosci. 2008 Mar;11(3):251-3. (PMID: 18246065)
Pharmacol Rev. 2021 Oct;73(4):298-487. (PMID: 34753794)
J Neurosci. 2010 Aug 18;30(33):11202-9. (PMID: 20720128)
Environ Health Perspect. 2011 Jun;119(6):866-72. (PMID: 21269927)
Science. 2006 Oct 6;314(5796):130-3. (PMID: 17023659)
Lancet Neurol. 2018 May;17(5):385-386. (PMID: 29525493)
Front Pharmacol. 2018 May 11;9:482. (PMID: 29867488)
Int J Neurosci. 2004 Jun;114(6):695-734. (PMID: 15204061)
J Med Chem. 2007 Apr 5;50(7):1558-70. (PMID: 17348638)
Front Synaptic Neurosci. 2020 Jul 10;12:26. (PMID: 32754026)
PLoS One. 2017 Feb 8;12(2):e0171538. (PMID: 28178321)
Transl Neurodegener. 2017 Oct 25;6:28. (PMID: 29090092)
Med Res Rev. 2007 Mar;27(2):239-78. (PMID: 16892196)
معلومات مُعتمدة: R01 AR078814 United States AR NIAMS NIH HHS; R01 CA206573 United States CA NCI NIH HHS; R01 NS083660 United States NS NINDS NIH HHS; R01 NS107253 United States NS NINDS NIH HHS
فهرسة مساهمة: Keywords: 4-BCCA; ALS; AMPA; Parkinson’s disease; antagonist; epilepsy; glutamate receptors; kainate receptors
تواريخ الأحداث: Date Created: 20231130 Latest Revision: 20240130
رمز التحديث: 20240130
مُعرف محوري في PubMed: PMC10683763
DOI: 10.3389/fcell.2023.1252953
PMID: 38033869
قاعدة البيانات: MEDLINE
الوصف
تدمد:2296-634X
DOI:10.3389/fcell.2023.1252953